For research use only
| Cat No. | ABC-X0289C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human CLIP1_LTK (F568C) BAF3 Cell Line facilitates functional studies of CLIP1_LTK fusion mutations in oncogenic signaling and cancer therapeutics.
Human CLIP1_LTK (F568C) BAF3 Cell Line is generated from murine Ba/F3 cells through stable lentiviral expression of the CLIP1-LTK fusion gene harboring the F568C point mutation. The cells are cultured at low passage numbers (<P20), with expression confirmed by qRT-PCR. Target CLIP1-LTK fusions are oncogenic in lung adenocarcinoma and hematologic malignancies. The F568C mutation enhances kinase activation, making it a valuable therapeutic target. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0289C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Useful for understanding LTK fusion-driven signaling and preclinical evaluation of LTK-targeted therapies in cancer research.